CD274 and breast carcinoma: In 2019, the European Commission and the Food and Drug Administration (FDA) approved atezolizumab combined with nab-paclitaxel in metastatic TNBC with positive PD-L1, which established the initial immunotherapy regimen approved for breast cancer patients [18].